Taiwan - Delayed Quote TWD

Panion & Bf Biotech Inc. (1760.TW)

70.00
+0.10
+(0.14%)
At close: May 9 at 1:30:09 PM GMT+8
Loading Chart for 1760.TW
  • Previous Close 69.90
  • Open 70.20
  • Bid 69.70 x --
  • Ask 70.00 x --
  • Day's Range 69.30 - 70.80
  • 52 Week Range 56.00 - 104.50
  • Volume 50,598
  • Avg. Volume 135,154
  • Market Cap (intraday) 6.002B
  • Beta (5Y Monthly) -0.28
  • PE Ratio (TTM) 48.28
  • EPS (TTM) 1.45
  • Earnings Date May 12, 2025
  • Forward Dividend & Yield 1.50 (2.14%)
  • Ex-Dividend Date Jun 13, 2024
  • 1y Target Est --

Panion & Bf Biotech Inc., a biotechnology pharmaceutical company, provides western medicines, cosmetics, and health care products in Taiwan, the United States, China, Hong Kong, and internationally. The company offers products in the areas of antibody, respiratory, gastrointestinal, Covid-19 IVD, antigen, anti-aging, active pharmaceutical ingredients, disease treatment, prevention, and veterinary products. It also offers nephrology, dermatology, pain management, hospital and household sanitization, and personal hygiene services. Panion & Bf Biotech Inc. was founded in 1974 and is headquartered in Taipei, Taiwan.

www.pbf.com.tw

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 1760.TW

View More

Performance Overview: 1760.TW

Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .

YTD Return

1760.TW
14.74%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
9.20%

1-Year Return

1760.TW
24.78%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
1.72%

3-Year Return

1760.TW
43.27%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
30.32%

5-Year Return

1760.TW
48.33%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
91.86%

Compare To: 1760.TW

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 1760.TW

View More

Valuation Measures

Annual
As of 5/8/2025
  • Market Cap

    5.99B

  • Enterprise Value

    6.14B

  • Trailing P/E

    48.21

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    2.95

  • Price/Book (mrq)

    3.12

  • Enterprise Value/Revenue

    3.02

  • Enterprise Value/EBITDA

    15.47

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    6.14%

  • Return on Assets (ttm)

    3.99%

  • Return on Equity (ttm)

    6.50%

  • Revenue (ttm)

    2.03B

  • Net Income Avi to Common (ttm)

    124.52M

  • Diluted EPS (ttm)

    1.45

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    558.37M

  • Total Debt/Equity (mrq)

    37.93%

  • Levered Free Cash Flow (ttm)

    93.15M

Research Analysis: 1760.TW

View More

Company Insights: 1760.TW

Research Reports: 1760.TW

View More

People Also Watch